Retatrutide Overview Retatrutide is a first-in-class investigational compound developed by Eli Lilly, currently being studied for its potential role in managing complex metabolic conditions, including obesity, type 2 diabetes, and fatty liver disease
PlexusDx serves patients with obesity and metabolic health challenges across all 50 states without requiring insurance
What the Research Shows Record-Setting Weight Loss in Clinical Trials The SURMOUNT-1 trial [1] established Zepbound as the most effective anti-obesity medication available
Here's the part that reframes everything: L-cells don't fire at random
New health and labeling requirements are slowing launches, and global misalignment is delaying market entry and increasing compliance costs
If nausea persists beyond 10 to 14 days, talk to your prescriber about holding at 0.5 mg for an extra 2 to 4 weeks before increasing further